CompletedNot Applicable

Prognostic Value of Three New Biomarkers of Multiple Sclerosis in Patients With Radiologically Isolated Syndrome

France100 participantsStarted 2018-07-01

Plain-language summary

To look at the prognostic value of new biomarkers in CSF and serum for characterisation of multiple sclerosis

Who can participate

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria * Patients have given their free consent for use of their samples in research * Patients have at least 2 years of clinical and radiological follow-up data available Exclusion criterion * No follow-up of patients

What they're measuring

Level of tumour necrosis factor receptor in cerebrospinal fluid

Timeframe: Baseline

Level of Neurofilament in cerebrospinal fluid

Timeframe: Baseline

Level of GFAP in cerebrospinal fluid

Timeframe: Baseline

Level of secreted glycoprotein in cerebrospinal fluid

Timeframe: Baseline

Trial details

NCT IDNCT03357887

SponsorCentre Hospitalier Universitaire de Nīmes

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2018-12-31

View on ClinicalTrials.gov More Multiple Sclerosis trials